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and Bo-jian Jiang1*Abstract
Background: To investigate on the expressions and the clinical significances of hepatocyte growth factor receptor
(c-MET), phosphorylated c-MET (p-MET) and e2f-1 transcription factor in primary lesion of gastric adenocarcinoma (GC).
Method: Tissue samples from the primary lesion of GC in patients who accepted D2/D3 radical gastrectomy with R0/R1
resection were stained by immunohistochemistry of c-MET, p-MET, e2f-1 and Ki-67. The univariate and the multivariate
analyses involving in clinicopathological parameters and prognostic factors were evaluated.
Results: The positivity rates for c-MET (66.12%, 80 cases/121 cases), p-MET (59.50%, 72 cases/121 cases), e2f-1 (38.84%,
47 cases/121 cases) and Ki-67 (72.73%, 88 cases/121 cases) in primary lesion of GC was significantly higher than that in
non-cancerous tissue at 5 cm places far from the margin of primary lesion (P < 0.05, respectively). The deeper tumor
invasion, the severer lymph node metastasis, the later stage of TNM and the higher expression of Ki-67 was respectively
an independent risk factor for the higher expression of c-MET or p-MET, but the younger age and the shorter survival
time was an independent risk factor for the higher expression of e2f-1 respectively. Survival analysis showed that the
worse prognosis could be observed in the patients with the combination of both c-MET-positive and e2f-1-negative
(P = 0.038) or both p-MET-positive and e2f-1-negative (P = 0.042). Cox analysis demonstrated that the severer lymphatic
node metastasis and the higher positivity rate of c-MET, p-MET or e2f-1 were an independent prognosis factor
respectively. The higher expression of e2f-1 was identified in patients with Stage I-II, which correlated with a shorter
survival time. Survival analysis also revealed that the prognosis of patients with positive expression of e2f-1 at Stage I-II
was significantly worse than that in patients with negative expression of e2f-1 (χ2 = 13.437, P = 0.001). However, in the
cases with Stage III-IV, no significant difference could be identified in the prognostic comparison between positive and
negative expressions of e2f-1.
Conclusions: The expression of c-MET or p-MET is an independent prognosis factor. It has been observed that the
higher expression of e2f-1 occurred in the early stages while the lower expression of it in the later stages in GC.
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Growth factors and their receptors, as factors influencing
cell cycle initiation, play an important role in the initiation
and the progression of tumor. The c-MET as the receptor
of hepatocyte growth factor (HGF) is an important
member of the growth factor receptor family, which is a
protein encoded by the c-MET proto-oncogene and is a* Correspondence: Jiang-bj2102@hotmail.com
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reproduction in any medium, provided the ortransmembrane protein mainly located at the cell mem-
brane. The c-MET has tyrosine kinase activity and has
connections with a variety of cancer gene-related products
and regulatory proteins. As well known, the binding of
HGF with c-MET can activate the Ras→ Raf→MEK→
MAPK protein signaling pathway. HGF also regulates the
activation of Ras by binding with small G proteins, namely
through the G protein, and is a second messenger as
cAMP, cGMP, DAG, PIP3, and Ca2+ signaling pathway,
which conveys a signal to the nucleus. This initiates or
shuts down the corresponding gene transcription, leading
to an increase or a decrease in the level of the cell cycle. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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release the transcription factor e2f [3,4]. E2f-1 has been
demonstrated to be a substantial member of the e2f
transcription factor family relating to the cell cycle and
the most important transcription activator of the Rb/e2f
pathway as involved in cell cycle regulation, which regu-
lates the transcription of the corresponding downstream
gene for the transition from phase G1 to phase S. Because
of this function, e2f-1 is considered to be essential for the
proliferation and the development of cells [5].
The over-expression and gene amplification of c-met
occurs during the initiation and the metastasis of many
tumors [6-8]. Furthermore, the role of e2f-1 is much
more complicated, having many functions of oncogenes
and tumor suppressor genes. As a nuclear antigen associ-
ated with cell proliferation-specificity, the Ki-67 can be
expressed in proliferating cells in all phases during cell
cycle except in phase G0 [9].
Gastric cancer is still the second cause of cancer-
related death worldwide [10,11], but the mechanisms of
initiation and metastasis of it have been still unclear until
now. Therefore, the relation of the expression of c-MET,
e2f-1 and Ki-67 with the profiles of clinicopathological
parameters and prognosis in the patients with gastric




A total of 121 patients with GC, who had undergone rad-
ical surgery (D2 or D3 operation) with R0 or R1 outcome
for GC from Jan 2001 to Dec 2008 in our department
(male = 77 cases, female = 44 cases), were registered in
this study of ours and were followed until May 31, 2011.
For these cases during this period, the clinical profiles
and the pathological features of them were recorded [12].
All of patients with advanced stages of GC would receive
the same scheme of chemotherapy with the (8–12) re-
gimes of 5-Fu and cisplatin after operation. Observing
data such as age (62.02 years as average), tumor diameter
(5.23 cm as average), metastatic lymph node ratio (35.89%
as average) and survival time (20.17 months as average)
were grouped with respect to the average values [13]. The
information of remaining parameters were listed in
Table 1. At the same time, specimens located at the places
more than 5 cm far from the margin of primary lesion of
cancer (so called as peri-cancer tissue) were taken and all
of them were pathologically confirmed as normal gastric
tissue at the same time. These samples from peri-cancer
tissues were used as controls to the relatively primary foci
of GC for the immunohistochemical staining [8,14,15].
This study was approved by the Ethical Committee of
Shanghai 3rd People’s Hospital, School of Medicine,
Shanghai Jiao-tong University before its start. Theinformed consent of each patient was obtained in written
file from the patient or his/her relative before the patient
participated in this study of ours. Written consent for
publication of this study was obtained from the patients
or their relative too.
Experimental reagents
The rabbit-derived monoclonal antibodies against human
such as anti-c-MET (D1C2; Cell Signaling TECHNOLOGY,
Beverly, MA), anti-c-MET phosphorylation (p-MET)
(Tyr1234/1235; D26; Cell Signaling TECHNOLOGY,
Beverly, MA), anti-e2f-1 (USCN Life Science Ltd Co.,
Wuhan, China) and anti-Ki-67 (USCN Life Science Ltd
Co., Wuhan, China) were used. The biotinylated second-
ary antibody was a goat anti-rabbit antibody (Changdao
Co., Shanghai, China). The kit of streptococcus avidin-
biotin-peroxidase complex (SABC) method and the DAB
chromogenic reagent were purchased from Changdao
Co., Shanghai, China.
Immunohistochemical staining procedure
The immunohistochemical staining method was used by
SABC method, and the procedure was based on the
product specifications. All tissue samples from primary
foci and the peri-cancer tissue (at 5 cm to the margin of
tumor as normal tissue checked by pathological observa-
tion) were fixed with 10% formalin, routinely embedded in
paraffin, cut into 4-μm thick as serial sections, dewaxed
with xylene, rehydration with an ethanol gradient, soak-
treated with 0.3% hydrogen peroxide solution, washed
with distilled water and placed in sodium citrate buffer.
The microwave heating method was adopted for antigen
retrieval. The samples were washed with PBS, blocked
with bovine serum and then incubated overnight at 4°C
with the primary antibody (1:100 dilutions). Biotinylated
second antibody was added, and the samples were incu-
bated for 30 min at room temperature. The samples were
washed with PBS to remove any unbound antibody. SABC
reagent was added, and then the samples were incubated
for 20 min at room temperature, washed with PBS, and
stained with DAB. Next the samples were washed with
distilled water, re-stained with hematoxylin. Finally, the
samples were dehydrated and made transparent, sealed
and examined with a microscope. PBS was used as a nega-
tive control instead of the primary antibody. A sample
provided by the company with known positive results was
used as a positive control.
Determination of the positive results
Two pathological researchers who were blind to the cor-
responding clinical and pathological data read the slices.
It was necessary to have the same results read by these two
researchers. If the different opinion for their observation
on the same sample occurred in these two pathological
Table 1 Expression of c-MET and its correlation with clinicopathological parameters in 121 cases
Parameters Grouping n c-MET [case (%)] χ2 test
Positive Negative χ2 value P value
Age (year) <60 40 28(70.0) 12(30.0) 0.366 0.562
≥60 81 52(64.2) 29(35.8)
Gender Male 77 52(67.5) 25(32.5) 1.835 0.168
Female 44 28(63.6) 16(36.4)
Tumor diameter (cm) <5 48 36(75.0) 12(25.0) 1.108 0.216
≥5 73 44(60.3) 29(39.7)
Location of tumor Cardia, fundus 20 17(65.0) 3(35.0) 11.239 0.003
Body 37 30(62.2) 7(37.8)
Pylorus, antrum 64 33(51.6) 31(48.4)
Lauren classification Intestinal 84 60(71.4) 24(28.6) 0.823 0.132
Diffuse 37 20(54.1) 17(45.9)
Histological type Grade 1 25 15(40.0) 10(60.0) 0.207 0.839
Grade 2 47 31(66.0) 16(34.0)
Grade 3 49 34(69.4) 15(30.6)
Invasion depth T1 18 10(55.6) 8(44.4) 1.928 0.116
T2 32 20(62.5) 12(37.5)
T3 30 21(70.0) 9(30.0)
T4 41 29(70.7) 12(29.3)
Metastatic lymph node ratio <35% 60 33(55.0) 27(45.0) 8.237 0.006
≥35% 61 47(67.0) 14(33.0)
Involving lymph node station N0 43 22(51.2) 21(48.8) 9.731 0.021
N1 41 30(73.2) 11(26.8)
N2 26 18(69.2) 8(30.8)
N3 11 10(90.9) 1(9.1)
TNM stages Ia 16 9(56.2) 7(43.8) 10.722 0.015
Ib 17 8(47.1) 9(52.9)
II 20 15(75.0) 5(25.0)
IIIa 20 14(70.0) 6(30.0)
IIIb 22 16(72.7) 6(26.3)
IV 26 18(69.2) 8/(30.8)
Survival (month) <20 75 57(76.0) 18(24.0) 11.337 0.001
≥20 46 23/(50.0) 23/(50.0)
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sample and then make the final decision on this obser-
vation. The evaluation criteria were as follows: a)
Brown-yellow was positive; five high power fields were
randomly selected for each slice and 500 cells were
counted. b) Positive rating: slices containing less than
5% positive cells were considered as negative expression,
and slices with greater or equal to 5% positive cells were
considered as positive expression. In summary, 5% ~
25%, 26% ~ 50%, and more than 50% positive cells were
respectively classified as weak, moderate and strong
positivity.Statistical analysis
SPSS 13.0 software (SPSS Inc., Chicago, IL) was used for
our analysis. A chi-square test was carried out to analyze
the relation of the expressions of c-MET, p-MET, e2f-1
and Ki-67 with the clinicopathological parameters respect-
ively. Two-category logistic regression analysis based on
multiple parameters was adopted to deduce the relation-
ship between the expression of c-MET, p-MET and e2f-1
and each parameter respectively. Univariate chi-square
analysis and bivariate Spearson relative analysis were
applied among the expression of c-MET, p-MET, e2f-1
and Ki-67. The Kaplan-Meier method and a log-rank test
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respectively. The Cox regression model for multiple
parameters influencing prognosis and the K-Related
Samples test were used to compare the average survival
times in different groups. P values less than 0.05 were
considered statistically significant.
Results
Tumor cells exhibiting brown granules were considered
positive. To be specific, the nuclear staining was primar-
ily observed for Ki-67, the membrane and cytoplasmic
staining were observed for c-MET and p-MET, and the
positive particles were observed in cytoplasm or nuclei
for e2f-1 (Figure 1). Overall, 66.12% (80 cases/121 cases)
of c-MET, 59.50% (72 cases/121 cases) of p-MET, 38.84%
(47 cases/121 cases) of e2f-1 and 72.73% (88 cases/121
cases) of Ki-67 as the positivity rates in primary lesion
were significantly higher than 34.71% (42 cases/121
cases; P = 0.001), 32.23% (39 cases/121 cases; P = 0.001),
14.88% (18 cases/121 cases; P = 0.005) and 29.75% (36
cases/121 cases; P = 0.002) in the non-cancerous tissue
respectively.
Relationship of expression of c-MET, p-MET and e2f-1
with clinicopathological characteristics
The significantly higher positivity rate of c-MET expres-
sion was respectively identified in the groups of the
tumor located in upper part of stomach (P = 0.003),
the ≥ 35% of metastatic lymph node ratio (P = 0.006),
the severer lymph node metastasis (P = 0.021), the later
stages of TNM (P = 0.015) and the ≥ 20 months ofFigure 1 Immunohistochemical staining for the primary foci of GC (SAaverage survival time (P = 0.001) in comparison with the
lower positivity rate of c-MET expression in the groups
of the tumor located in the lower and middle parts of
stomach, the < 35% of metastatic lymph node ratio, the
milder lymph node metastasis, the earlier stages of
TNM and the < 20 months of average survival time
(Table 1).
The significantly higher positivity rate of p-MET ex-
pression was respectively found in the groups of the
tumor located in upper part of stomach (P = 0.009),
the ≥ 35% of metastatic lymph node ratio (P = 0.007),
the severer lymph node metastasis (P = 0.042), the later
stages of TNM (P = 0.016) and the ≥20 months of aver-
age survival time (P = 0.004) in comparison with the
lower positivity rate of p-MET expression in the
groups of the tumor located in the lower and middle
parts of stomach, the < 35% of metastatic lymph node
ratio, the milder lymph node metastasis, the earlier
stages of TNM and the < 20 months of average survival
time (Table 2).
However, the significantly higher positivity rate of e2f-1
expression was respectively observed in the groups of the
tumor with ≥ 5 cm (P = 0.001), the ≥ 35% of metastatic
lymph nodes ratio (P = 0.013), the deeper invasion of
tumor (P = 0.003), the later stages of TNM (P = 0.017) and
the ≥ 20 months of average survival time (P = 0.005) in
comparison with the lower positivity rate of e2f-1 expres-
sion in the groups of the tumor with < 5 cm, the < 35%
of metastatic lymph node ratio, the slighter invasion of
tumor, the earlier stages of TNM and the < 20 months of
average survival time (Table 3).BC method). Notes: A: c-MET; B: p-MET, C: Ki-67; D: e2f-1.
Table 2 Expression of p-MET and its correlation with clinicopathological parameters in 121 cases
Parameters Grouping n p-MET [case (%)] χ2 test
Positive Negative χ2 value P value
Age (year) <60 40 24(60.0) 16(40.0) 0.766 0.862
≥60 81 48(59.3) 33(40.7)
Gender Male 77 48(62.3) 29(37.7) 1.976 0.187
Female 44 24(54.5) 20(45.5)
Tumor diameter (cm) <5 48 33(68.8) 15(31.3) 1.138 0.236
≥5 73 39(53.4) 34(46.6)
Location of tumor Cardia, fundus 20 15(75.0) 5(25.0) 10.252 0.009
Body 37 27(73.0) 10(27.0)
Pylorus, antrum 64 30(46.9) 34(53.1)
Lauren classification Intestinal 84 55(65.5) 29(34.5) 0.924 0.186
Diffuse 37 17(45.9) 20(54.1)
Histological type Grade 1 25 13(52.0) 12(48.0) 0.192 0.741
Grade 2 47 28(59.6) 19(40.4)
Grade 3 49 31(63.3) 18(36.7)
Invasion depth T1 18 9(50.0) 9(50.0) 1.996 0.156
T2 32 18(56.3) 14(43.8)
T3 30 19(63.3) 11(36.7)
T4 41 26(63.4) 15(36.6)
Metastatic lymph node ratio <35% 60 30(50.0) 30(50.0) 8.556 0.007
≥35% 61 42(68.9) 19(31.1)
Involving lymph node station N0 43 20(46.5) 23(53.5) 9.651 0.042
N1 41 27(65.9) 14(34.1)
N2 26 16(61.5) 10(38.5)
N3 11 9(81.8) 2(18.2)
TNM stages Ia 16 8(50.0) 8(50.0) 10.887 0.016
Ib 17 8(47.1) 9(52.9)
II 20 13(65.0) 7(35.0)
IIIa 20 13(65.0) 7(35.0)
IIIb 22 14(63.6) 8(36.4)
IV 26 16(61.5) 10/38.5)
Survival (month) <20 75 52(69.3) 23(30.7) 10.006 0.004
≥20 46 20/(43.5) 26/(56.5)
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and e2f-1
The higher positivity rate of c-MET was significantly corre-
lated with the higher positivity rate of p-MET expression
(P = 0.001) or Ki-67 expression (P < 0.001) respectively.
And the higher positivity rate of p-MET was significantly
correlated with the higher positivity rate of Ki-67 expres-
sion (P < 0.001). By relative analysis, the positive expression
of c-MET was positively related to the positive expression
of p-MET (P = 0.001). And the positive expression of either
c-MET (P < 0.001) or p-MET (P < 0.001) was positivelyrelated with the positive expression of Ki-67 respectively
also (Table 4).
Logistic analysis regarding to the expressions of c-MET,
p-MET and e2f-1
Multivariate analysis revealed that the deeper tumor inva-
sion [P = 0.017, 95.0% CI. for Exp (B) = 0.000 ~ 0.368], the
severer lymph node metastasis [P = 0.010, 95.0% CI. for
Exp (B) = 0.000 ~ 0.253], the later stage of TNM [P = 0.009,
95.0% CI. for Exp (B) = 4.390 ~ 354.32] and the higher
expression of Ki-67 [P = 0.001, 95.0% CI. for Exp (B) =
Table 3 Expression of e2f-1 and its correlation with clinicopathological parameters in 121 cases
Parameters Grouping n e2f-1 [case (%)] χ2 test
Positive Negative χ2 value P value
Age (year) <60 40 17(42.5) 23(57.5) 0.336 0.562
≥60 81 30(37.0) 51(63.0)
Gender Male 77 32(41.6) 45(58.4) 0.657 0.418
Female 44 15(34.1) 29(65.9)
Tumor diameter (cm) <5 48 27(56.3) 21(43.7) 10.148 0.001
≥5 73 20(23.4) 53(76.6)
Location of tumor Cardia, fundus 20 7(35.0) 13(65.0) 0.226 0.893
Body 37 14(37.8) 23(62.2)
Pylorus, antrum 64 26(60.6) 38(59.4)
Lauren classification Intestinal 84 36(42.9) 48(57.1) 1.863 0.172
Diffuse 37 11(29.7) 26(70.3)
Histological type Grade 1 25 10(40.0) 15(60.0) 0.236 0.889
Grade 2 47 17(36.2) 30(63.8)
Grade 3 49 20(40.8) 29(59.2)
Invasion depth T1 18 12(66.7) 6(33.3) 14.143 0.003
T2 32 17(53.1) 15(46.9)
T3 30 7(23.3) 23(76.7)
T4 41 11(26.8) 30(73.2)
Metastatic lymph node ratio <35% 60 30(50.0) 30(50.0) 6.237 0.013
≥35% 61 17(27.9) 44(72.1)
Involving lymph node station N0 43 21(48.8) 22(51.2) 6.739 0.081
N1 41 17(41.5) 24(58.5)
N2 26 8(30.8) 18(69.2)
N3 11 1(9.1) 10(90.91)
TNM stages Ia 16 10(62.5) 6(37.5) 13.724 0.017
Ib 17 8(47.1) 9(52.9)
II 20 11(55.0) 9(45.0)
IIIa 20 8(40.0) 12(60.0)
IIIb 22 6(27.3) 16(72.7)
IV 26 7(26.9) 19(73.1)
Survival (month) <20 75 52(69.3) 23(30.7) 10.356 0.005
≥20 46 20/(43.5) 26/(56.5)
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higher expression of c-MET respectively.
At the same time, the multivariate analysis showed that
the deeper tumor invasion [P = 0.025, 95.0% CI. for Exp
(B)= 0.000 ~ 0.468], the severer lymph node metastasis [P =
0.021, 95.0% CI. for Exp (B) = 0.000 ~ 0.358], the later stage
of TNM [P = 0.011 95.0% CI. for Exp (B) = 3.390 ~ 302.37]
and the higher expression of Ki-67 [P = 0.034, 95.0% CI. for
Exp (B) = 2.898 ~ 54.943] were the independent risk factors
for the higher expression of p-MET respectively.
However, the younger age [P = 0.011, 95.0% CI. for
Exp (B) = 0.897 ~ 0.986] and the shorter survival time[P = 0.028, 95.0% CI. for Exp (B) = 0.933 ~ 0.996] were
the independent risk factors for the higher expression of




As shown in Table 5, log-rank analysis of prognosis dem-
onstrated that the correlated factors with worse prognosis
included the ≥ 5 cm tumor in diameter (P = 0.002), the
tumor located in cardia, fundus and body of stomach (P =
0.017), the deeper invasion of tumor (P = 0.008), the ≥35%
Table 4 Chi-square analysis and Spearson relative analysis among the expression of c-MET, p-MET, e2f-1 and Ki-67
Parameters c-MET expression (n/%)
Positive Negative χ2 value P1 value




P-MET Positive 70/57.9 2/1.7 28.765 0.001 0.635 0.001
Negative 10/8.3 39/32.2
e2f-1 Positive 33/27.3 14/11.6 0.766 0.290 0.142 0.395
Negative 47/38.8 27/22.3
Ki-67 Positive 70/57.8 18/14.9 28.262 <0.001 0.621 <0.001
Negative 10/8.3 23/19.0
p-MET expression (n/%)
e2f-1 Positive 29/24.0 18/14.9 0.811 0.308 0.195 0.518
Negative 43/35.5 31/25.6
Ki-67 Positive 66/54.5 22/18.2 29.233 <0.001 0.667 <0.001
Negative 6/5.0 27/22.3
e2f-1 expression (n/%)
Ki-67 Positive 35/28.9 53/43.8 0.021 0.858 −0.018 0.861
Negative 12/9.9 21/17.4
Note: *: Chi-square analysis, #: Spearson relative analysis.
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lymph nodes metastasis (P < 0.001), the later stages of
TNM (P < 0.001), the higher positivity rate of c-MET ex-
pression (P = 0.001) (Figure 2A), the higher positivity rate
of p-MET expression (P < 0.001) (Figure 2B), the lower
positivity rate of e2f-1 expression (P = 0.036) (Figure 2C)
and the higher positivity rate of Ki-67 expression (P =
0.002). Survival analysis also revealed that the worse prog-
nosis was observed in the patients with the combination of
both c-MET-positive and e2f-1-negative (P = 0.038) or both
p-MET-positive and e2f-1-negative (P = 0.042). As shown
by Cox stepwise regression model analysis (items to ob-
serve included in the standard univariate analysis P < 0.05),
the severer lymph nodes metastasis [P < 0.001, 95.0% CI
for Exp (B) = 1.504 ~ 2.747] and the higher positivity rate
of c-MET expression [P = 0.038, 95.0% CI for Exp (B) =
1.152 ~ 3.005], p-MET expression [P = 0.035, 95.0% CI for
Exp (B) = 1.005 ~ 2.981] or e2f-1 expression [P = 0.032,
95.0% CI for Exp (B) = 1.058 ~ 3.602] shared the worse
prognosis respectively. As revealed by the Cox model ana-
lyses for the relationship of prognosis with the positivity
rates of 4 factors, 3 factors and 2 factors in combination
with c-MET, p-MET, e2f-1 and Ki-67, the positivity of all 4
factors was the independently prognostic factor [P = 0.003,
95.0% CI for Exp (B) = 1.033 ~ 4.323] and the positivity of
3 factors of p-MET, e3f-1, Ki-67 was also the independ-
ently prognostic factor [P = 0.012, 95.0% CI for Exp (B) =
1.015 ~ 4.023]. But the positivity in other combination of
these factors was not independently prognostic factor.
However, other variate such as tumor location, tumor size,invasion depth, TNM stage and higher expression of Ki-67
was not the independently prognostic factors too.
Connection of c-MET, p-MET or e2f-1 subgroup regarding to
positivity rate with prognosis
Analysis on subgroup of either c-MET positive expres-
sion or p-MET positive expression revealed that the
average survival month of the strongly positive group
[(15.1 ± 2.9) mo, P = 0.002] was significantly shorter than
that in the moderately [(22.1 ± 3.3) mo.] and weakly
[(29.8 ± 3.8) mo.] positive groups, and simultaneously,
that the average survival month of the strongly positive
group [(16.5 ± 4.1) mo, P = 0.003] was significantly
shorter than that in the moderately [(23.0 ± 2.9) mo.]
and weakly [(30.1 ± 4.1) mo.] positive groups. However,
the analysis of e2f-1 expression subgroup demonstrated
that the average survival month of the strongly positive
group [(15.4 ± 2.7) mo., P = 0.017] was also significantly
shorter than that in the moderately [(22.5 ± 2.9) mo.]
and weakly [(26.2 ± 2.8) mo.] positive groups.
Stratified analysis on prognosis
Performing the correlation of e2f-1 expression with
prognosis among patients with different TNM stages of
GC generated the results as follows: the total positivity
rate of e2f-1 expression was 41.3% (50 cases/121 cases),
and the positivity rates for Stage Ia, Ib, II, IIIa, IIIb and
IV were 62.5% (10 cases/16 cases), 47.1% (8 cases/17
cases), 55% (11 cases/20 cases), 40% (8 cases/20 cases),
27.3% (6 cases/22 cases) and 26.9% (7 cases/26 cases),
Table 5 Survival analysis on all case by Log-rank analysis (n = 121)
Parameters Grouping Case number (n/%) χ2 value df P value
Tumor diameter (cm) <5 48/(39.7) 9.190 1 0.002
≥5 73/(60.3)
Tumor location Cardia, fundus 20/(16.5) 8.122 2 0.017
Body 37/(30.6)
Pylorus, antrum 64/(52.9)








Metastatic lymph node ratio <35% 60/(49.6) 8.596 1 0.003
≥35% 61/(50.4)






c-MET expression Positive 80/(66.1) 12.084 1 0.001
Negative 41/(33.9)
p-MET expression Positive 72(59.5) 5.687 1 <0.001
Negative 49(40.5)
e2f-1 expression Positive 47/(38.8) 3.217 1 0.036
Negative 74/(61.2)
Ki-67 expression Positive 88/(72.7) 9.348 1 0.002
Negative 33/(27.3)
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at a higher level in patients with Stage I-II, and that the
higher expression of e2f-1 correlated with a shorter sur-
vival time in the early stage of GC. On the other hand,
lower expression of e2f-1 was observed in patients with
Stage III-IV, but no connection between e2f-1 expression
and survival time was observed in patients with Stage III-
IV based on statistical analysis (Table 6). Survival rate
analysis by log-rank showed that the prognosis of patients
positive for the expression of e2f-1 at Stage I-II was
significantly worse than that in patients negative for the
expression of e2f-1 (χ2 = 13.437, P = 0.001). However,
such difference for the prognosis of patients between the
positive and negative for the expression of e2f-1 was not
significant among patients during Stage III-IV (χ2 = 0.283,
P = 0.595) (Figure 2D and 2E).Discussions
Requirements for molecular classification about
prognostic improvements
To choose the optimal treatment in order to improve the
prognosis of GC, it is necessary to seek more sensitive indi-
cators for the early diagnosis and much more exquisite
choice for the optimal treatment. Such indicators as tumor
invasion depth, the number of regional lymph node metas-
tases, distant metastasis and histological grade were used
in UICC classification [16], but the different catalog in sta-
tions for regional lymph nodes according to tumor location
and the different stage based on some comprehensive
evaluation such as liver metastasis, peritoneal metastasis
and ascites cytology were applied in JGCA [12]. Both of
these two classifications aimed at evaluating diseases status
more accurately, choosing treatments more appropriate
Figure 2 Postoperative long-term survival curves regarding to the expression of c-MET, p-MET and e2f-1. Notes: A: Grouped by c-MET
expression (P = 0.001); B; Grouped by p-MET expression (P = 0.001). C: Grouped by e2f-1 expression (P = 0.036). D: In patients with stages I and II
grouped by e2f-1 positive and negative expression; E: In patients with stages III and IV grouped by e2f-1 positive and negative expression.
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cacy. Because of the the complexity and the diversity in
the initiation, development and metastasis of tumor as re-
vealed by evidences of molecular biology, it was found that
both lymph node metastasis and the abnormal expression
of a variety of biological molecules in the primary tumorsand the metastatic foci of GC could lead to the different
prognosis in GC [8,13-15,17]. As revealed in this study of
ours, although severer lymph node metastasis was the in-
dependently prognostic factor, the TNM stage could not
be identified as the independently prognostic factor, which
might be due to the occurrences of deviations in both of













Stage I-II < 20 19/36.5 9/17.3 4.792 0.029 −0.304 0.029
≥ 20 9/17.3 15/28.8
Stage III-IV < 20 10/14.5 37/53.6 2.895 0.081 0.205 0.091
≥ 20 9/13.0 13/18.8
Notes: *: Log-rank analysis; #: K-Related Samples test.
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well as in micro-metastasis of lymph node [13,17]. There-
fore, the molecular classification applying the merits of
tumor markers in molecular biology in GC might be of
some supplements to overcome the deviation and the fault-
inesses of either UICC classification or JGCA classification.
Regulation of c-MET, p-MET and e2f-1
Tumor cells are characterized by abnormal cell cycle initi-
ation coupled with unrestricted proliferation. The start of
the cell cycle is inseparable from growth factors. If growth
factors are lacking during the G1 phase, the cell cycle will
stop at the restriction point and the cell will pass into the
quiescent state, namely the G0 phase. G0 phase cells enter
G1 phase when stimulated by growth factors. The binding
of a growth factor with its receptor induces a signal which
activates Cyclin D-Cdk4/6 and phosphorylates Rb, thereby
releasing the e2f transcription factor, which is mainly made
up of e2f-1. This process in turn gives rise to the transcrip-
tion of several genes, driving the cell cycle to continue and
mediating the transition from phase G1 to phase S [18].
The c-MET binding to HGF causes the growth, the
proliferation and the differentiation of the target cell. The
incremental expression of c-MET has been identified in
hepatocellular carcinoma, gastric carcinoma and colon
carcinoma [7,19,20]. Extensive expression of c-MET,
especially p-MET as activated c-MET, in GC was identi-
fied during this research of ours. Furthermore, either
c-MET or p-MET is more often highly expressed in cases
with tumor located in the upper part of stomach, larger
than 35% of metastatic lymph node ratio, severer lymph
node involvement, <20 months of survival, later stage of
TNM and stronger proliferation of cells (higher expres-
sion of Ki-67). Thus, it could be proposed that either
c-MET or p-MET was a useful marker of the malignant
behavior of GC and an effective factor for the prognosis
of GC. However, it is necessary for these more precise
conclusions to do the further investigations.
Recently, the relationship between e2f-1 and apoptosis
of tumor cells, which plays a complicated role in the
generation and progression of many kinds of tumors,
has received more attention as revealed by experimental
study [21]. E2f-1 is able to bind with the promoter of
the insulin-like growth factor-I receptor (IGF-IR) genein prostate cancer cells to promote the transcription of
IGF-IR, thus enhancing the proliferation of tumor cells
[22]. The over-expression of e2f-1 in non-small cell lung
cancer can activate the expressions of thymidylate syn-
thase and survivin, and then encourage the proliferation
of tumors, finally resulting in the worse prognosis [23].
On the other hand, some reports have proposed that e2f-1
might suppress cancer cells. For the elucidation to this
phenomenon, e2f-1 can bind directly to promoter of the
BIN1 tumor-suppressor gene when DNA is damaged, then
trans-activating BIN1 to induce apoptosis. E2f-1 can also
activate the gene Cancer 1, another tumor-suppressor
gene whose promoter is methylated [24,25]. Our univari-
ate analysis from the samples of human GC showed that
e2f-1 was more highly expressed in patients at Stage I and
II. Furthermore, multivariate analysis coupled with TNM-
stratified analysis revealed that patients who were positive
for e2f-1 expression at the cases with Stage I and II had
worse prognoses. Thus, this outcome to seem of contra-
diction hinted that e2f-1 might be a key transcription
factor which stimulated the conversion from normal cells
to cancer cells; therefore, it might be why its expression
was markedly lower in the later periods of progression of
GC.
E2f-1 can induce apoptosis in many types of tumor cells,
which has been demonstrated by in vitro gene transfection
experiments [26]. Enhanced invasion of advanced GC
might be related to the decreased expression of e2f-1,
which might transcriptionally regulate down several tumor-
suppressing genes and apoptosis-related genes. However,
many pathways could not regulate oncogenes. Therefore,
tumor cell proliferation and survival were further out of
control. As such, e2f-1 might potentially inhibit tumor cells
and shed new light on the choice of gene therapy for
patients with late-stage of tumors after revealing in detail
on the more clear mechanism of this regulation.
Based on classical signaling pathways, c-MET is an up-
stream molecule to e2f-1. E2f-1 should be regulated by
p-MET as the active status of c-MET, but we could not
find such connection either between c-MET and e2f-1
(r = 0.142, P = 0.395) or between p-MET and e2f-1 (r =
0.195, P = 0.518). This indicates that in addition to being
a target molecule of c-MET, e2f-1 may be regulated by
some other signaling pathways, which is worthy of making
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pathway. Nevertheless, when the expression of e2f-1 was
lower during the later stages of advanced GC, c-MET and
p-MET were still highly expressed. Therefore, further
investigation for the relationship of p-MET with e2f-1 is
required to verify this hypothesis in clinical and experi-
mental studies.
Conclusion
The expression of either c-MET or its activity status, i.e.
p-MET, is one of the markers reflecting the degree of ma-
lignancy of GC, and either c-MET or p-MET is an effec-
tive prognosis factor because the significantly shorter
survival time of patients positive for expression of c-MET
and p-MET. E2f-1 was highly to express in relatively earlier
stages of GC, while the lower expression of e2f-1 was ob-
served in later periods of GC. As such, e2f-1 could play dif-
ferent roles at different stages of cancer; that is, it might
promote the formation of the cancer in the early stages but
inhibit the progression of cancer in the intermediate and
advanced stages.
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